Cabaletta Bio prices $35M public offering of common stock and pre-funded warrants

Cabaletta Bio, Inc.

Offering of 126,815 shares at $5.52/share and pre-funded warrants to purchase 6,213,776 shares at $5.51999 each.
Gross proceeds of ~$35M; net proceeds ~$32.5M after underwriting discounts and expenses.
Oversubscribed offering with participation from Venrock, Adage Capital, Cormorant, and others.
Net proceeds to fund CABA-201 preclinical and IND, and ongoing DSG3-CAART and MuSK-CAART trials.
Closing expected December 12, 2022; Cowen and Evercore acted as joint book-running managers.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cabaletta Bio, Inc. entered into Underwriting Agreement with Cowen and Company, LLC and Evercore Group L.L.C. (effective 2022-12-07).

Action: entry
Agreement: underwriting
Counterparty: Cowen and Company, LLC and Evercore Group L.L.C.
Effective: 2022-12-07

Exact text from the filing

On December 7, 2022, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC and Evercore Group L.L.C. (collectively, the “Underwriters”), relating to an underwritten offering

View on SEC.gov

Browse all material agreements →

Cabaletta Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-302822

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.